Yelena Janjigian
MD
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center

Yelena Y. Janjigian MD, is Associate Professor and Chief of Gastrointestinal (GI) Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Her research career and clinical practice are focused on improving treatment outcomes for patients with GI malignancies. She is an international expert in the management of cancers of esophagus and stomach and lead several seminal studies that changed practice and set the standard of care for these diseases. She produced high impact publications describing the genomic basis for esophagogastric cancer pathogenesis and secure federal grants to fund future studies. Her research is focused on developing new treatments, with a special emphasis on defining the therapeutically relevant molecular characteristics of tumors in the GI tract, with 120 peer-reviewed publications to date.

Dr. Janjigian received her BS from the University of California, San Diego and her MD from the New York University School of Medicine. She did her internal medicine residency at New York School of Medicine/Bellevue Hospital and her hematology/oncology fellowship training at MSKCC. She joined the MSK faculty in 2009 as a member of the GI Oncology Service.

Dr. Janjigian is an active member of American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and European Society for Medical Oncology (ESMO) holding an array of leadership positions. As Chief of the GI Oncology Service, Dr. Janjigian’s mission is to foster research and innovation that transform the future of GI oncology to help patients worldwide

Sessions

Register
General Session

Welcome

Friday, May 17, 2024
9:15 AM - 9:25 AM
General Session

Session 1: Debate: Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors or Claudin-18.2 (CLDN18.2)? DISCUSSION

Friday, May 17, 2024
9:55 AM - 10:05 AM
General Session

Session 2: Debate: MSI Tumors: Does Anatomic Location Affect the Management? Yes vs No: DISCUSSION

Friday, May 17, 2024
10:35 AM - 10:45 AM
General Session

Session 3: Debate: Management of Gastric Cancer With Limited Peritoneal Carcinomatosis - Cytoreduction and HIPEC for All: Yes vs No - DISCUSSION

Friday, May 17, 2024
11:45 AM - 11:55 AM
General Session

Session 6: Debate: Germline Testing for Gastrointestinal Tumors for all Irrespective of Tumor Origin: Yes vs No - DISCUSSION

Friday, May 17, 2024
2:55 PM - 3:05 PM
General Session

Session 7: Debate: Is ctDNA Ready for Prime Time for Detection of Molecular Residual Disease? Yes vs No - DISCUSSION

Friday, May 17, 2024
4:45 PM - 4:55 PM
General Session

Session 8: Debate: Is There A Role for Immune Checkpoint Inhibition Outside of A Clinical Trial in Microsatellite Stable (MSS) Patients? Yes vs No - DISCUSSION

Friday, May 17, 2024
5:25 PM - 5:35 PM
General Session

Welcome

Saturday, May 18, 2024
8:00 AM - 8:05 AM
General Session

Session 9: Debate: Transarterial Chemoembolization for Hepatocellular Carcinoma with Immune Checkpoint Blockade: Skip it or Do it? DISCUSSION

Saturday, May 18, 2024
8:35 AM - 8:45 AM
General Session

Session 10: Debate: Cholangiocarcinoma - Immune Checkpoint Blockade for All: Yes vs No - DISCUSSION

Saturday, May 18, 2024
9:15 AM - 9:25 AM